<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum>http://feeds.feedburner.com/AmericanBankingNews</forum>
<forum_title>American Banking News</forum_title>
<discussion_title>Vertex Pharmaceuticals Incorporated (VRTX) Given “Buy” Rating at Robert W. Baird</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.americanbankingnews.com/2016/04/25/vertex-pharmaceuticals-incorporated-vrtx-given-buy-rating-at-robert-w-baird/</topic_url>
<topic_text>
Tweet 
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ‘s stock had its “buy” rating restated by equities researchers at Robert W. Baird in a research report issued on Monday, MarketBeat reports. 
Vertex Pharmaceuticals ( NASDAQ:VRTX ) traded down 1.8792% during mid-day trading on Monday, reaching $85.1689. The company’s stock had a trading volume of 757,375 shares. Vertex Pharmaceuticals has a one year low of $75.90 and a one year high of $143.45. The stock has a 50-day moving average price of $83.75 and a 200-day moving average price of $103.35. The company’s market capitalization is $20.98 billion. 
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, January 27th. The pharmaceutical company reported $0.17 EPS for the quarter, meeting analysts’ consensus estimates of $0.17. During the same period in the previous year, the company posted ($0.55) earnings per share. The business earned $417.94 million during the quarter, compared to analysts’ expectations of $406.30 million. Vertex Pharmaceuticals’s quarterly revenue was up 189.0% on a year-over-year basis. Equities research analysts forecast that Vertex Pharmaceuticals will post $1.99 EPS for the current year. 
A number of other equities research analysts have also recently commented on VRTX. Leerink Swann reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Saturday, February 6th. Cowen and Company reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Sunday, April 17th. RBC Capital reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Saturday, March 19th. Maxim Group reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, January 19th. Finally, BMO Capital Markets began coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, April 7th. They set a “market perform” rating and a $90.00 price target on the stock. Six investment analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Vertex Pharmaceuticals has a consensus rating of “Buy” and an average price target of $135.03. 
A number of hedge funds have bought and sold shares of VRTX. Beacon Capital Management acquired a new stake in Vertex Pharmaceuticals during the fourth quarter worth about $0. Everence Capital Management Inc. boosted its position in shares of Vertex Pharmaceuticals by 34.5% in the fourth quarter. Everence Capital Management Inc. now owns 5,492 shares of the pharmaceutical company’s stock valued at $691,000 after buying an additional 1,410 shares in the last quarter. Baird Financial Group Inc. boosted its position in shares of Vertex Pharmaceuticals by 16.9% in the fourth quarter. Baird Financial Group Inc. now owns 8,343 shares of the pharmaceutical company’s stock valued at $1,050,000 after buying an additional 1,207 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Vertex Pharmaceuticals during the first quarter valued at $684,000. Finally, Ameritas Investment Partners Inc. boosted its position in shares of Vertex Pharmaceuticals by 0.9% in the fourth quarter. Ameritas Investment Partners Inc. now owns 8,698 shares of the pharmaceutical company’s stock valued at $1,094,000 after buying an additional 78 shares in the last quarter. 
In related news, Director Joshua S. Boger sold 11,200 shares of the stock in a transaction that occurred on Wednesday, January 27th. The stock was sold at an average price of $93.22, for a total transaction of $1,044,064.00. Following the completion of the sale, the director now directly owns 265,284 shares of the company’s stock, valued at approximately $24,729,774.48. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website . Also, CFO Ian F. Smith sold 12,084 shares of the stock in a transaction that occurred on Wednesday, February 3rd. The stock was sold at an average price of $90.84, for a total value of $1,097,710.56. Following the sale, the chief financial officer now directly owns 112,999 shares of the company’s stock, valued at $10,264,829.16. The disclosure for this sale can be found here . 
Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets.  //www.americanbankingnews.com/2016/04/25/vertex-pharmaceuticals-incorporated-vrtx-given-buy-rating-at-robert-w-baird/   Vertex Pharmaceuticals Incorporated   Vertex Pharmaceuticals Incorporated  
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.americanbankingnews.com/2016/04/25/vertex-pharmaceuticals-incorporated-vrtx-given-buy-rating-at-robert-w-baird/</post_url>
<post_date>20160425</post_date>
<post_time>1841</post_time>
<username>ABMN Staff</username>
<post>
Tweet 
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ‘s stock had its “buy” rating restated by equities researchers at Robert W. Baird in a research report issued on Monday, MarketBeat reports. 
Vertex Pharmaceuticals ( NASDAQ:VRTX ) traded down 1.8792% during mid-day trading on Monday, reaching $85.1689. The company’s stock had a trading volume of 757,375 shares. Vertex Pharmaceuticals has a one year low of $75.90 and a one year high of $143.45. The stock has a 50-day moving average price of $83.75 and a 200-day moving average price of $103.35. The company’s market capitalization is $20.98 billion. 
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, January 27th. The pharmaceutical company reported $0.17 EPS for the quarter, meeting analysts’ consensus estimates of $0.17. During the same period in the previous year, the company posted ($0.55) earnings per share. The business earned $417.94 million during the quarter, compared to analysts’ expectations of $406.30 million. Vertex Pharmaceuticals’s quarterly revenue was up 189.0% on a year-over-year basis. Equities research analysts forecast that Vertex Pharmaceuticals will post $1.99 EPS for the current year. 
A number of other equities research analysts have also recently commented on VRTX. Leerink Swann reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Saturday, February 6th. Cowen and Company reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Sunday, April 17th. RBC Capital reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Saturday, March 19th. Maxim Group reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, January 19th. Finally, BMO Capital Markets began coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, April 7th. They set a “market perform” rating and a $90.00 price target on the stock. Six investment analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Vertex Pharmaceuticals has a consensus rating of “Buy” and an average price target of $135.03. 
A number of hedge funds have bought and sold shares of VRTX. Beacon Capital Management acquired a new stake in Vertex Pharmaceuticals during the fourth quarter worth about $0. Everence Capital Management Inc. boosted its position in shares of Vertex Pharmaceuticals by 34.5% in the fourth quarter. Everence Capital Management Inc. now owns 5,492 shares of the pharmaceutical company’s stock valued at $691,000 after buying an additional 1,410 shares in the last quarter. Baird Financial Group Inc. boosted its position in shares of Vertex Pharmaceuticals by 16.9% in the fourth quarter. Baird Financial Group Inc. now owns 8,343 shares of the pharmaceutical company’s stock valued at $1,050,000 after buying an additional 1,207 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Vertex Pharmaceuticals during the first quarter valued at $684,000. Finally, Ameritas Investment Partners Inc. boosted its position in shares of Vertex Pharmaceuticals by 0.9% in the fourth quarter. Ameritas Investment Partners Inc. now owns 8,698 shares of the pharmaceutical company’s stock valued at $1,094,000 after buying an additional 78 shares in the last quarter. 
In related news, Director Joshua S. Boger sold 11,200 shares of the stock in a transaction that occurred on Wednesday, January 27th. The stock was sold at an average price of $93.22, for a total transaction of $1,044,064.00. Following the completion of the sale, the director now directly owns 265,284 shares of the company’s stock, valued at approximately $24,729,774.48. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website . Also, CFO Ian F. Smith sold 12,084 shares of the stock in a transaction that occurred on Wednesday, February 3rd. The stock was sold at an average price of $90.84, for a total value of $1,097,710.56. Following the sale, the chief financial officer now directly owns 112,999 shares of the company’s stock, valued at $10,264,829.16. The disclosure for this sale can be found here . 
Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets.  //www.americanbankingnews.com/2016/04/25/vertex-pharmaceuticals-incorporated-vrtx-given-buy-rating-at-robert-w-baird/   Vertex Pharmaceuticals Incorporated   Vertex Pharmaceuticals Incorporated  
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image>http://www.americanbankingnews.com/logos/vertex-pharmaceuticals-logo.png</main_image>
</document>
